The safety of intraocular methotrexate in silicone-filled eyes

Retina

Volumn 28, Issue 8, 2008, Pages 1082-1086

  Hardwig, Paul W ^a   Pulido, Jose S ^a   Bakri, Sophie J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Intravitreal methotrexate; Proliferative diabetic retinopathy; Proliferative vitreoretinopathy; Silicone oil; Uveitis

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; METHOTREXATE; SILICONE OIL; SILICONE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD EYE BARRIER; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG SAFETY; ENDOPHTHALMITIS; EYE EXAMINATION; EYE SURGERY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; LOCAL THERAPY; MALE; PHACOEMULSIFICATION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; UVEITIS; VISION; VISUAL ACUITY; VITREORETINOPATHY; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; EYE; EYE DISEASE; INJECTION; INTRAOCULAR HYPOTENSION; VITREOUS BODY;

COHORT STUDIES; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; EYE DISEASES; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; METHOTREXATE; OCULAR HYPOTENSION; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; SILICONES; UVEITIS; VISUAL ACUITY; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 58149218468     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181754231     Document Type: Article

References (16)

1. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108:1134- 1139.
2. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-1156.
3. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intra-vitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-1716.
4. Hardwig PW, Pulido JS, Erie JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006;142:883-885.
5. de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 1999;83:448-451.
6. Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001;119:1518-1524.
7. Jarus G, Blumenkranz M, Hernandez E, Sossi N. Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology 1985;92:91-96.
8. Cobo LM, Forster FK. The clearance of intravitreal gentamicin. Am J Ophthalmol 1981;92:59-62.
9. Kane A, Barza M, Baum J. Intravitreal injection of gentamicin in rabbits. Effect of inflammation and pigmentation on half-life and ocular distribution. Invest Ophthalmol Vis Sci 1981;20:593-597.
10. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
11. Case JL, Peyman GA, Barrada A, et al. Clearance of intravitreal 3H-fluorouracil. Ophthalmic Surg 1985;16:378-381.
12. Deng SX, Penland S, Gupta S, et al. Methotrexate reduces the complications of endophthalmitis resulting from intravitreal injection compared with dexamethasone in a rabbit model. Invest Ophthalmol Vis Sci 2006;47:1516-1521.
13. Pharmaceutical Compounding: Sterile Preparations. The United States Pharmacopeia 30/The National Formulary 25. The United States Pharmacopeial Convention; Rockville, MD: 2006; vol 1:334-351.
14. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290.
15. Barrada A, Peyman GA, Greenberg D, et al. Toxicity of antineoplastic drugs in vitrectomy infusion fluids. Ophthalmic Surg 1983;14:845-847.
16. Fiscella R, Peyman GA, Elvart J, Yue B. In vitro evaluation of cellular inhibitory potential of various antineoplastic drugs and dexamethasone. Ophthalmic Surg 1985;16:247-249.